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Abstract Malignant mesothelioma is an asbestos-induced,
aggressive tumour with limited treatment options and very
poor outcome. Currently, there are no tumour biomarkers in
widespread clinical use for this disease. Soluble mesothelin is
the most intensively investigated mesothelioma biomarker
and has been approved by the US FDA primarily as a tool
for monitoring patient response and progression. Mesothelin
is elevated in the blood and effusions of patients with meso-
thelioma, and is rarely elevated in people with benign disease
with normal renal function. However, the sensitivity of
mesothelin limits its use as a stand-alone tool for the screening
of the asymptomatic asbestos-exposed population—one of the
primary aims of mesothelioma biomarker studies. Thus, there
is an intense research effort focused on the identification of
new and/or novel biomarkers for mesothelioma. Some of the
challenges associated with biomarker discovery in mesotheli-
oma are discussed.
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Introduction
Intense interest has focussed on identifying and validating
new biomarkers for disease, including for cancer. The first
of the so-called traditional circulating blood cancer bio-
markers, carcinoembryonic antigen (CEA) and alpha-
fetoprotein were identified in the 1960s. Since then, only 13
blood-based and four urine-based cancer biomarkers have re-
ceived approval for clinical use from the US Food and Drug
Administration (FDA), a level of approval which is consid-
ered the “gold standard” for clinically useful biomarker dis-
covery [1].
A large number of candidate biomarkers have been report-
ed in the literature. For these new biomarkers to be brought to
the clinic, they must offer advantages over existing bio-
markers or clinical procedures in terms of improved sensitiv-
ity and specificity or prognostic or predictive ability and must
fulfil specific clinical needs, as well as being cost-effective [2].
The majority of biomarkers approved by the FDA are ap-
proved for use in a monitoring setting. However, biomarkers
have been proposed for many different settings of disease
management, including diagnosis, prognosis, risk stratifica-
tion, guiding therapy selection, overall management and pop-
ulation screening. Interests in biomarker discovery not only
stem from the potential health benefits but also the huge eco-
nomic potential following the introduction of a new test into
the health care system [3].
Malignant mesothelioma
For mesothelioma, an asbestos-induced tumour with very
poor patient outcome, 5-year survival rates of less than 5 %
are routinely reported [4]. Finding a biomarker that could
enable early detection of mesothelioma, before symptoms de-
velop, has been a driving focus for researchers. There is
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evidence that screening can impact on cancer-specific mortal-
ity particularly for breast, bowel and cervical cancers with
reports of significant decreases in disease-specific mortality
following screening programmes [5]. However, for mesothe-
lioma, no effective treatment is available. Proponents of early
diagnosis for mesothelioma suggest that a timely diagnosis
provides the opportunity to offer treatment to patients at an
earlier time when tumours are smaller, localised and more
accessible to treatments. There is some limited evidence to
support this; intra-cavity immunotherapeutic trials from
France showed that if malignant mesothelioma was detected
early, the disease could potentially be treated in a less aggres-
sive manner and more successfully [6]. Also, in a non-trial
setting, a selected group of patients, those presenting with
early stage disease and treated with multimodality therapy
(surgery, postoperative chemotherapy with or without radia-
tion therapy), have been reported to have a 46 % 5-year sur-
vival [7].
Clearly, differences exist in the requirements for a biomark-
er intended as a screening tool for a population compared to a
biomarker for triaging symptomatic individuals. In individ-
uals already presenting with symptoms, the risks associated
with surgical confirmation of a malignant diagnosis would
generally be acceptable whereas the rate of false positives in
a screening programmewould need to beminimised if surgery
was to be a confirmatory tool. Thus, a biomarker with very
high specificity would be required in such a setting. False
positives could be minimised by only screening high risk in-
dividuals, and for mesothelioma, this would be those exposed
to a moderately high level of asbestos. However, data on as-
bestos exposure is not well standardised. Many biomarker
studies in the literature present patient-reported categorical
data (i.e. exposed/unexposed/unknown), as opposed to data
derived from lung asbestos fibre burden, job exposure matrix-
es or correlates with atmospheric asbestos loads.
Mesothelin
We have been studying mesothelin as a biomarker for malig-
nant mesothelioma for over 12 years. Mesothelin was origi-
nally identified as a glycophoshatidylinositol-linked glyco-
protein of approximately 40 kDa present on the cell surface
of mesothelial cells and some cancer types including ovarian,
pancreatic and lung carcinomas; squamous cell carcinomas of
the oesophagus and cervix and mesothelioma [8]. In collabo-
ration with Ingegerd and Karl Eric Hellstrom, we identified
that a soluble form of mesothelin was present in the blood at
high levels in mesothelioma patients [9]. At the time, this
protein was termed soluble mesothelin-related peptide
(SMRP). Subsequently, it has been found that the detected
protein is in the majority a soluble form of the cell surface
mesothelin identified by Pastan and colleagues in 1994 that is
shed into the circulation [10, 11].
In our original publication, we described elevated levels of
mesothelin in the blood of 84 % of a relatively modest total
number of mesothelioma patient samples (n=44) using an in-
house assay [9]. For comparison, we examined levels of the
protein in samples collected in our clinics from patients with
other malignant and benign pulmonary diseases, some of
whom had been exposed to asbestos, and also from a cohort
of younger, female, healthy laboratory volunteers. In these
early studies, a positive cut-off value was defined as three
standard deviations above the average mesothelin value for
the non-asbestos-exposed controls. Using this cut-off, 1 of
22 patients with asbestosis and 1 of 22 patients with idiopathic
pulmonary fibrosis, plus 1 of 22 patients with non-small cell
lung cancer were mesothelin positive; 157 patients with in-
flammatory or malignant pulmonary or pleural diseases other
than MM were negative. Of the positive patients, one had an
elevated creatinine at the time of the sample, a factor since
shown to elevate blood mesothelin levels.
In hind-sight, there were a number of issues with the orig-
inal design and implementation of the 2003 study. Firstly, the
cut-off was defined in the same sample set as the sensitivity
and specificity was calculated from and also that the control
“healthy group” were markedly different from the cases.
However, a strength of the study was the relatively large num-
ber of clinically relevant controls examined, controls that were
collected in the same centre, under the same conditions and in
the same time frame as the cases.
The mesothelin assay was advanced for commercial devel-
opment, and the availability of this standardised assay which
was simple and easy to use enabled many different laborato-
ries around the world to independently verify that mesothelin
was elevated in the blood of mesothelioma patients. Indeed, a
meta-analysis examining the data from 16 studies at eleven
different laboratories from 1026 individual mesothelioma pa-
tients and 3465 controls of various aetiologies, including
healthy individuals, those with benign disease and those with
malignancy, concluded that elevated serum mesothelin is a
strong predictor for mesothelioma, but that the marker lacks
the sensitivity to be used in early diagnosis [12••].
Biomarker discovery
Various genomic, proteomic, immunomic, imaging and other
tools have been used to identify, quantify and characterise
novel biomarkers for many different diseases. There are ad-
vantages and disadvantages to the various biomarker discov-
ery platforms. Common problems for all platforms include the
high false discovery rate and the identification of tens to hun-
dreds of potential biomarkers in discovery phases that need to
be validated. There is also a poor rate of conversion of
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biomarkers identified in discovery projects to clinically vali-
dated bioassays that provide favourable health impacts. Sev-
eral biomarker discovery pipelines have been proposed to
maximise the efficiency of translation of biomarker discovery
to clinical implementation. The process can be broken into six
steps: discovery, validation, verification, assay development,
retrospective clinical validation and prospective clinical eval-
uation and then followed by, the not unchallenging steps, of
commercialisation and “deployment into the clinic”. General-
ly speaking, the number of patient samples analysed increases
as the candidate biomarker proceeds down the pipeline [13,
14]. Clearly, the steps in the pipeline can be tailored to specific
clinical questions or discovery platforms. Critical for the pro-
cess is that independent validation of biomarker performance,
ideally in multiple centres, is performed; however, the accept-
able levels of evidence required depend on many factors, par-
ticularly the clinical context the biomarker will eventually be
put to.
One particularly challenging question for biomarker dis-
covery is the choice of sample type for use in the discovery
step. As blood is likely to be the sample that will be used
clinically, it is attractive to use this in the discovery phase.
However, human blood is a very complex mixture comprising
of over tens of thousands of proteins that span more than ten
orders of magnitude in terms of protein abundance from albu-
min at 50 mg/mL down to some cytokines present at the 5 pg/
mL range [15]. In addition, the 22 most abundant proteins,
which are unlikely cancer biomarkers, account for 99 % of
blood protein content and could mask the identification of low
abundant proteins where cancer biomarkers are likely to be
discovered. Generally, clinical biomarkers (i.e. mesothelin,
PSA, etc) are found in the nanogramme/millilitre range, and
it is believed that novel biomarkers will be at this concentra-
tion or less. The dynamic range and complexity of the plasma
proteome causes extreme difficulties in identifying low abun-
dance markers directly in the blood [16]. Therefore, studies
have either performed a prior extraction step to remove these
abundant proteins or used various alternative fluids in which it
is hoped that the tumour markers would be at higher concen-
tration due to proximity to the tumour tissue, and have reduced
complexity. Such samples include tumour tissue, pleural effu-
sion and cell lines. However, such sample choice simply pres-
ent different inherent complications including tumour tissue
heterogeneity, the presence (or absence) of stroma and the
effect of changes to the cell induced by culturing.
Another fundamental issue in biomarker discovery projects
is the choice of comparator group if a biomarker is planned for
diagnosis (or ultimately screening). Normal/healthy controls
are generally employed in biomarker discovery studies; how-
ever, the average mesothelioma patient is a man in his 70s and
this group tends to have various comorbidities. The best con-
trols for a diagnostic study would be those patients presenting
with symptoms indicative of the disease under study. For
screening, a non-symptomatic but otherwise matched popula-
tion is required. Another useful control for screening studies is
longitudinal samples from the same individual.
Further influencing the choice of “normal” control group
used for comparative purposes in biomarker discovery studies
is the biospecimen type used (i.e. blood, tumour, proximal
fluid or cell lines). For example, normal pleural fluid is diffi-
cult to ethically obtain; non-malignant (normal) cells in cul-
ture generally have significantly different proliferation rates
than cancerous cell lines, and the use of immortalised, for
example viral transformed cell lines, is particularly artificial.
In a simple case-control comparison, the demonstration of
a statistically significant difference in the mean level of the
biomarker between groups is not necessarily sufficient to in-
dicate that a biomarker would be clinically useful. Indeed, in
some cases, a t test p<0.05 is simply reflective of low vari-
ability in the control group. Recently, it was elegantly de-
scribed how the variability of biomarker levels as well as
quantitative difference in means between groups gives a better
predictor of potential biomarker clinical value. After account-
ing for such differences and the proportion of cases expressing
a given biomarker, Skates and colleagues estimated, for a
given discovery set sample size, the probability of validating
a given biomarker in the verification stage [17••]. This ap-
proach highlights that more factors than the results of a Stu-
dent’s t test need to be accounted for in biomarker discovery
studies and that many “true” biomarkers do not necessarily
meet the demands of the clinic.
A commonly recognised problem in biomarker studies is
that the original study shows great promise but subsequent
studies do not have such strong results. Possible reasons for
the lack of success in identifying new biomarkers can occur in
each of the steps in the discovery pipeline including problems
and biases related to experimental design, data analysis, sam-
ple collection, processing and/or storage [18, 19]. Further-
more, problems arise from the high variability and the lack
of replication performed in some discovery platforms which
result in a high rate of false positive candidates. Lack of
standardisation in discovery platforms is being addressed by
the National Cancer Institute’s Clinical Proteomic Technology
Assessment for Cancer Network [20–22]. Filtering of false
positive candidates identified in the discovery stage can also
be achieved through the use of orthologous techniques in the
secondary validation and verification stages using assays with
purportedly greater assay precision (such as antibody-based
techniques), though some of the problems associated with
sampling can be carried over to this step. Another factor that
is becoming clearer now is the accuracy of commercially
available “research-only” ELISA kits. In our own studies,
we have found significant discrepancy between two different
ELISAs for the mesothelioma biomarker, megakaryocyte po-
tentiating factor (MPF), whereby in matching samples one
assay resulted in a sensitivity of 29 % and the other 52 % at
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a specificity of 95 % [23, 24]. MPF is the 30-kDa N-terminal
protein product of the MSLN gene [25, 26]. Using robust
assays, MPF conveys equivalent diagnostic information to
the mesothelin biomarker in distinguishing mesothelioma
from other diseases [23, 27••]. Whilst MPF should be consid-
ered an acceptable biomarker for mesothelioma, it is unlikely
to be able to contribute anything additional to patient out-
comes than the mesothelin biomarker.
Biomarker discovery in mesothelioma
A review of the literature finds over twenty soluble bio-
markers reported for mesothelioma which were identified on
a variety of discovery platforms: genomic, proteomic and
immunomic. Three recent examples which reported very high
diagnostic accuracy in a case-control setting include a panel of
13 biomarkers discovered using SOMAmer proteomic tech-
nology [28], fibulin-3 discovered following mRNA expres-
sion studies [29] and an autoantibody biomarker panel [30].
Few of these reportedmesothelioma biomarkers have yet been
independently validated or translated to the clinic and the rea-
sons for this vary.
The SOMAmer panel was identified using aptamer tech-
nologies and was reported to have excellent diagnostic accu-
racy with an area under the receiver operator characteristic
(AUC) curve value of 0.99±0.01 in the discovery set and
0.95±0.04 in the validation set of samples for distinguishing
mesothelioma cases from asbestos-exposed controls. The 13
component proteins were mostly associated with inflammato-
ry and proliferative functions [28]. To date, however, there
have been no follow-up publications. Given the specialised
nature of the aptamer platform used for this study, it is unlikely
that the panel could be independently validated although with
a significant commitment of time and resources, it may be
possible to validate the candidates individually using
ELISA-based assays.
Several potential mesothelioma candidate biomarkers have
been identified principally as differentially expressed mole-
cules following mRNAmicroarray studies [31–34]. However,
in general, there was little consistency in the lists of candidates
identified in different studies and of the candidates identified;
few have been subject to follow-up biomarker studies. One of
the potential candidates that has been examined as a blood-
based marker is osteopontin, which was reported to have an
AUC of 0.9 (95 % CI 0.82–0.95) for distinguishing mesothe-
lioma stage I cases from asbestos-exposed controls [35]. How-
ever, these results were not replicated in independent cohort
studies which found that osteopontin had a low specificity for
mesothelioma [24, 36], although there were several problems
associated with the sample type and sample stability that in-
fluenced these findings.
Another potential candidate biomarker identified following
mRNA expression studies was fibulin-3, a secreted glycopro-
tein. Fibulin-3 mRNAwas found to be on average significant-
ly overexpressed by 7.36-fold from 37 surgical mesothelioma
tumours compared with matched normal peritoneum [31]. In a
follow-up study to examine fibulin-3 as a fluid-based bio-
marker, an initial impressive diagnostic accuracy for mesothe-
lioma was reported; plasma fibulin-3 had a sensitivity of over
96 % at a specificity of 95 %, and pleural effusion fibulin-3 a
84 % sensitivity at a 93 % specificity using a commercial
ELISA for the protein (USCN Life Science) [29]. In subse-
quent sample sets, however, sensitivity was noticeably less,
estimated to be 40 % in Canadian samples [29] and 22 % in
Australian samples [37] at a 95 % specificity. This is another
example of a biomarker that showed great promise in early
studies but, as is common with biomarkers, has not subse-
quently been proven to be useful.
For mesothelioma, as in other disease settings, the vast
majority of published biomarker discovery papers report the
discovery of a marker with expression levels significantly
higher in cases relative to controls. That is statistical signifi-
cance is the favoured study end-point rather than clinical or
practical relevance. Whilst there have been suggestions that
biomarker studies not be published until independent valida-
tion in external samples is performed, preferably in a clinical
setting, we feel this is an unrealistic expectation given the push
not only of researchers, but research institutes, universities,
the media and even funding bodies for ground-breaking re-
search with a direct clinical impact to be rapidly published.
How to reconcile these two aims is not clear. Also, in many
instances, if preliminary biomarker evidence remains unpub-
lished due to imperfect validation, then other researchers with
the appropriate resources to investigate these biomarkers with
their own clinical samples may remain unaware of the poten-
tial of the biomarker, and a validation opportunity consequent-
ly lost. It is imperative that all suitable studies for a biomarker
are reported and subsequently evaluated in a meta-analysis
before the final utility of a biomarker can be decided.
Would we have found mesothelin today using a discovery
platform?
Mesothelin was identified as a biomarker for mesothelioma
primarily based upon existing biological understanding of the
tumour. An interesting question however is, if we were to
examine some of the data available from high-throughput
screening platforms being used in the untargeted search for
novel mesothelioma biomarkers, would we have found
mesothelin?
The probability of mesothelin being identified in an unbi-
ased biomarker study can be estimated using the assumptions
described by Skates and colleagues [17••]. The available data
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for this purpose for mesothelin as a blood biomarker is that
approximately 50 % of mesothelioma cases express the mark-
er at diagnosis, that there is relatively limited variability of
mesothelin levels in control samples and there are four or
more standard deviations of the mean difference between the
mean mesothelin levels in controls relative to cases (Fig. 1a).
Using these assumptions, a biomarker discovery experiment
limited to ten case and control samples (because of either cost
constraints or availability of “normal” tissue) and with 100
samples available for the verification stage, would have ap-
proximately a 50 % probability of identifying mesothelin.
Indeed examining the publically available mRNA expres-
sion data [38] (GEO accession GSE2549), mesothelin was
clearly expressed in mesothelioma surgical specimens whilst
not being measurable in four out of five normal pleural tissue
samples analysed (Fig. 1b). Although the focus of the Gordon
manuscript was not to identify biomarkers but rather improve
understanding of mesothelioma tumourgenesis and pathobiol-
ogy, in supplementary data they show that mesothelin was
overexpressed approximately 14-fold in tumours relative to
normal lung and pleural tissue (p<0.005). However, examin-
ing our own unpublished dataset of mRNA expression in me-
sothelioma cell lines and normal mesothelial cell cultures, we
found no difference in the levels of mesothelin mRNA be-
tween the groups. This finding possibly reflects the observa-
tion that mesothelin is one of several molecules whose expres-
sion is downregulated in tissue culture [39].
Examining publically available quantitative mass
spectrometry-based proteomic data, mesothelin was found to
be present in the proteome ofmesothelioma effusions (Fig. 1c)
but was not identified as a candidate biomarker following
analysis comparing proteins differentially expressed between
mesothelioma and lung cancer [40] (ProteomeXchange iden-
tifier PXD000531). In our own unpublished proteomic
dataset, mesothelin was only shown to be differentially
expressed in one of three experiments.
Thus, whether or not mesothelin would have appeared on
any list of candidate biomarkers following an unbiased anal-
ysis on a high throughput discovery platformwould have been
dependent, as expected, upon the biospecimen used (either
tumour tissue, cell lines or effusions) as well as the comparator
groups evaluated.
Conclusion
At present, the only example of a FDA-approved biomarker
that was identified through a high-throughput screening bio-
marker discovery strategy is the OVA1® (Vermillion, USA)
assay [41•]. Of note, OVA1 is not approved for use in a diag-
nostic setting but in a specific clinical setting of triaging wom-
en with pelvic masses to specific centres for surgical interven-
tion. The OVA1 test consists of four proteins identified by
SELDI-TOF mass spectrometry plus CA125, a well-
established ovarian cancer biomarker. The panel of markers
has a greater specificity than CA125 used alone. We hope that
a similar approach, using a panel of biomarkers, might be
successful for mesothelioma. Despite a large number of bio-
markers being reported for mesothelioma in the literature,
mesothelin remains the single-best blood-based biomarker
for the cancer and is considered to be the “gold standard”
against which new biomarkers need to be judged and remains
























































































Fig. 1 Mesothelin expression. a Summary data of serum mesothelin
concentrations determined by MESOMARK ELISA in mesothelioma
patients (MM) and people with asbestos exposure (and normal kidney
function) compiled from data collected in our own laboratory over
10 years. b Messenger RNA expression data as determined by
Affymetrix expression arrays in mesothelioma (MM) tissue and cell
lines, relative to expression in the SV40-transformed immortalised Me-
t5A mesothelial cell line and in normal pleural tissue as reported by
Gordon et al. [34]. c Relative mesothelin derived peptide expression as
determined by quantitative mass spectrometry-based proteomics in me-
sothelioma (MM), lung adenocarcinoma (LAC) and benign pleural effu-
sions as reported by Mundt et al. [40]
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